LQDA Strangle Strategy
LQDA (Liquidia Corporation), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
LQDA (Liquidia Corporation) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $5.12B, a trailing P/E of 227.23, a beta of 0.42 versus the broader market, a 52-week range of 11.85-57.8, average daily share volume of 1.5M, a public-listing history dating back to 2018, approximately 170 full-time employees. These structural characteristics shape how LQDA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.42 indicates LQDA has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 227.23 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.
What is a strangle on LQDA?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current LQDA snapshot
As of May 15, 2026, spot at $57.15, ATM IV 75.23%, IV rank 10.83%, expected move 21.57%. The strangle on LQDA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.
Why this strangle structure on LQDA specifically: LQDA IV at 75.23% is on the cheap side of its 1-year range, which favors premium-buying structures like a LQDA strangle, with a market-implied 1-standard-deviation move of approximately 21.57% (roughly $12.33 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated LQDA expiries trade a higher absolute premium for lower per-day decay. Position sizing on LQDA should anchor to the underlying notional of $57.15 per share and to the trader's directional view on LQDA stock.
LQDA strangle setup
The LQDA strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With LQDA near $57.15, the first option leg uses a $60.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed LQDA chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 LQDA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $60.00 | $3.20 |
| Buy 1 | Put | $54.00 | $3.00 |
LQDA strangle risk and reward
- Net Premium / Debit
- -$620.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$620.00
- Breakeven(s)
- $47.80, $66.20
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
LQDA strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on LQDA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$4,779.00 |
| $12.65 | -77.9% | +$3,515.49 |
| $25.28 | -55.8% | +$2,251.98 |
| $37.92 | -33.7% | +$988.48 |
| $50.55 | -11.5% | -$275.03 |
| $63.19 | +10.6% | -$301.46 |
| $75.82 | +32.7% | +$962.05 |
| $88.46 | +54.8% | +$2,225.55 |
| $101.09 | +76.9% | +$3,489.06 |
| $113.73 | +99.0% | +$4,752.57 |
When traders use strangle on LQDA
Strangles on LQDA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the LQDA chain.
LQDA thesis for this strangle
The market-implied 1-standard-deviation range for LQDA extends from approximately $44.82 on the downside to $69.48 on the upside. A LQDA long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current LQDA IV rank near 10.83% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on LQDA at 75.23%. As a Healthcare name, LQDA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to LQDA-specific events.
LQDA strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. LQDA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move LQDA alongside the broader basket even when LQDA-specific fundamentals are unchanged. Always rebuild the position from current LQDA chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on LQDA?
- A strangle on LQDA is the strangle strategy applied to LQDA (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With LQDA stock trading near $57.15, the strikes shown on this page are snapped to the nearest listed LQDA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are LQDA strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the LQDA strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 75.23%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$620.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a LQDA strangle?
- The breakeven for the LQDA strangle priced on this page is roughly $47.80 and $66.20 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current LQDA market-implied 1-standard-deviation expected move is approximately 21.57%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on LQDA?
- Strangles on LQDA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the LQDA chain.
- How does current LQDA implied volatility affect this strangle?
- LQDA ATM IV is at 75.23% with IV rank near 10.83%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.